Memantine Hydrochloride Tablet
Product Images NDC 33342-297

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 33342-297). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

112 (Memantine Hydrochloride Tablets 10 mg 500)

Label for Memantine Hydrochloride Tablets, USP 10 mg, an oral tablet manufactured by Macleods Pharmaceuticals Limited. The label includes storage instructions, prescription-only status, and packaging quantity of 500 tablets from Macleods Pharma USA.*

FDA Label Image

121 (Memantine Hydrochloride Tablets 10 mg 60)

Label for Memantine Hydrochloride Tablets, USP 10 mg oral tablets. The label shows the product name with strength prominently displayed. It includes manufacturer information listing Macleods Pharmaceuticals Limited in India and Macleods Pharma USA, Inc. in New Jersey as the manufacturer and distributor. The package count is 60 tablets. Storage and dispensing instructions are also visible.*

FDA Label Image

111 (Memantine Hydrochloride Tablets 5 mg 60)

Label for Memantine Hydrochloride Tablets USP 5 mg oral tablets, containing 60 tablets per container. The label shows Macleods Pharma USA as the manufacturer and Macleods Pharmaceuticals Ltd. as the manufacturer address in Baddi, Himachal Pradesh, India. It includes storage instructions and usage notes, and displays the NDC 33342-297-09.*

FDA Label Image

Figure1 (Memantine Hydrochloride Tablets Figure1)

Chemical structure of Memantine Hydrochloride, showing the molecular arrangement with NH2 and HCl groups attached to a bicyclic ring system with methyl substituents.*

FDA Label Image

Figure2 (Memantine Hydrochloride Tablets Figure2)

A line graph showing mean change from baseline in ADCS ADL score over 28 weeks of treatment. The graph compares Placebo and Memantine Hydrochloride Tablet groups, with Placebo showing a greater decline and Memantine Hydrochloride Tablet showing less decline. Clinical improvement and decline reference lines are marked on the y-axis.*

FDA Label Image

Figure3 (Memantine Hydrochloride Tablets Figure3)

A cumulative percentage curve graph comparing the ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living) change from baseline in patients taking Memantine Hydrochloride tablets versus placebo. The x-axis denotes ADCS-ADL change values, and the y-axis shows cumulative percentage of patients. Two lines represent patient outcomes for Memantine Hydrochloride and placebo groups respectively.*

FDA Label Image

Figure4 (Memantine Hydrochloride Tablets Figure4)

A line graph comparing mean change from baseline in SIB score over 28 weeks of treatment between Memantine Hydrochloride Tablet and placebo groups. The x-axis shows weeks of treatment (0 to 28), and the y-axis shows mean change scores from baseline with error bars. The placebo group shows a decline in scores over time, while the Memantine Hydrochloride group remains near baseline with minimal change. The graph includes labels for clinical improvement and clinical decline.*

FDA Label Image

Figure5 (Memantine Hydrochloride Tablets Figure5)

A cumulative percentage plot comparing patients treated with Memantine Hydrochloride Tablet versus placebo, showing SIB change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph uses squares to represent placebo data and circles for Memantine Hydrochloride Tablet data.*

FDA Label Image

Figure6 (Memantine Hydrochloride Tablets Figure6)

A line graph depicting mean change from baseline in ADCS-ADL score over 24 weeks of treatment. It compares Placebo/Donepezil with Memantine Hydrochloride Tablet/Donepezil, showing clinical improvement and decline trends with error bars for variability.*

FDA Label Image

Figure7 (Memantine Hydrochloride Tablets Figure7)

A cumulative percentage of patients graph showing ADCS-ADL change from baseline on the x-axis and the cumulative percentage of patients on the y-axis. The graph compares two groups: Placebo/Donepezil and Memantine Hydrochloride Tablet/Donepezil. Data points for Placebo/Donepezil are marked with squares, and a line represents Memantine Hydrochloride Tablet/Donepezil.*

FDA Label Image

Figure8 (Memantine Hydrochloride Tablets Figure8)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment. It compares Placebo/Donepezil and Memantine Hydrochloride Tablet/Donepezil groups, indicating trends of clinical improvement or decline with error bars at each time point.*

FDA Label Image

Figure9 (Memantine Hydrochloride Tablets Figure9)

A cumulative percentage graph showing patients' SIB change from baseline for three groups: Placebo/Donepezil, Memantine Hydrochloride Tablet/Donepezil, and another unspecified group. The x-axis represents SIB change from baseline, and the y-axis shows the cumulative percentage of patients. The plot compares treatment effects over a range of changes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.